Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 703	$ 1,168	$ 2,799	$ 3,948
General and administrative	2,125	1,632	4,602	4,247
Total operating expenses	2,828	2,800	7,401	8,195
Operating loss	(2,828)	(2,800)	(7,401)	(8,195)
Other income:
Interest income (expense), net	130	45	434	57
Other income	1		1	9
Interest and other income, net	131	45	435	66
Net loss	$ (2,697)	$ (2,755)	$ (6,966)	$ (8,129)
Net loss per share, basic	$ (0.87)	$ (1.98)	$ (2.33)	$ (5.88)
Net loss per share, diluted			$ (2.33)	$ (5.88)
Weighted average number of common shares outstanding, basic (In Shares)	3,105,956	1,391,481	2,983,916	1,382,118
Weighted average number of common shares outstanding, diluted (In Shares)	3,105,956	1,391,481	2,983,916	1,382,118